Warning: file_put_contents(/opt/frankenphp/design.onmedianet.com/storage/proxy/cache/0218d34363d44a08fe3ffb1de43a2a60.html): Failed to open stream: No space left on device in /opt/frankenphp/design.onmedianet.com/app/src/Arsae/CacheManager.php on line 36

Warning: http_response_code(): Cannot set response code - headers already sent (output started at /opt/frankenphp/design.onmedianet.com/app/src/Arsae/CacheManager.php:36) in /opt/frankenphp/design.onmedianet.com/app/src/Models/Response.php on line 17

Warning: Cannot modify header information - headers already sent by (output started at /opt/frankenphp/design.onmedianet.com/app/src/Arsae/CacheManager.php:36) in /opt/frankenphp/design.onmedianet.com/app/src/Models/Response.php on line 20
4-AcO-MALT - Wikipedia Jump to content

4-AcO-MALT

From Wikipedia, the free encyclopedia

4-AcO-MALT
Clinical data
Other names4-Acetoxy-MALT; 4-Acetoxy-N-methyl-N-allyltryptamine
Drug classSerotonin receptor modulator; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC16H20N2O2
Molar mass272.348 g·mol−1
3D model (JSmol)
  • C=CCN(CCc1c[nH]c2c1c(ccc2)OC(=O)C)C
  • InChI=InChI=1S/C16H20N2O2/c1-4-9-18(3)10-8-13-11-17-14-6-5-7-15(16(13)14)20-12(2)19/h4-7,11,17H,1,8-10H2,2-3H3
  • Key:PGBFYUDKPCYIEB-UHFFFAOYSA-N

4-AcO-MALT, or 4-acetoxy-MALT, also known as 4-acetoxy-N-methyl-N-allyltryptamine, is a psychedelic drug of the tryptamine family.[1][2][3] It is the acetate ester of 4-HO-MALT.[1][2][3]

The drug is assumed to act as a prodrug of the serotonergic psychedelic 4-HO-MALT.[1] 4-HO-MALT is a serotonin receptor modulator, including acting as an agonist of the serotonin 5-HT2 receptors.[2] The receptor interactions of 4-AcO-MALT have also been studied.[2][3]

4-AcO-MALT was first described in the scientific literature by at least 2021.[1] It was encountered as a novel designer drug.[4][5]

See also

[edit]

References

[edit]
  1. ^ a b c d Pham DN, Chadeayne AR, Golen JA, Manke DR (1 February 2021). "Psilacetin derivatives: fumarate salts of the methyl–ethyl, methyl–allyl and diallyl variants of the psilocin prodrug". Acta Crystallographica Section E. 77 (Pt 2): 101–106. Bibcode:2021AcCrE..77..101P. doi:10.1107/S2056989021000116. ISSN 2056-9890. PMC 7869532. PMID 33614134.
  2. ^ a b c d Glatfelter GC, Naeem M, Pham DN, Golen JA, Chadeayne AR, Manke DR, et al. (April 2023). "Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice". ACS Pharmacology & Translational Science. 6 (4): 567–577. doi:10.1021/acsptsci.2c00222. PMC 10111620. PMID 37082754.
  3. ^ a b c Jain MK, Gumpper RH, Slocum ST, Schmitz GP, Madsen JS, Tummino TA, et al. (July 2025). "The polypharmacology of psychedelics reveals multiple targets for potential therapeutics" (PDF). Neuron. doi:10.1016/j.neuron.2025.06.012. PMID 40683247.
  4. ^ Miller JJ, Yazdanpanah M, Colantonio DA, Beriault DR, Delaney SR (2024). "New Psychoactive Substances: A Canadian perspective on emerging trends and challenges for the clinical laboratory". Clinical Biochemistry. 133–134 110810. doi:10.1016/j.clinbiochem.2024.110810. PMID 39181179.
  5. ^ Axelsson MA, Lövgren H, Kronstrand R, Green H, Bergström MA (2022). "Retrospective identification of new psychoactive substances in patient samples submitted for clinical drug analysis". Basic & Clinical Pharmacology & Toxicology. 131 (5): 420–434. doi:10.1111/bcpt.13786. ISSN 1742-7835. PMID 36028947.
[edit]